# Kura Oncology, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Kura Oncology, Inc.). ## Overview Kura Oncology, Inc. is a U.S.-based biopharmaceutical company focused on precision medicines for cancer, with a pipeline built around small-molecule therapies that target cancer signaling pathways. The company evolved from a research-stage developer into a commercial-stage oncology business after FDA approval of ziftomenib, marketed as KOMZIFTI, for relapsed or refractory NPM1-mutated AML. ## Products & services • KOMZIFTI (ziftomenib) oral menin inhibitor for AML • Ziftomenib clinical programs in frontline and relapsed/refractory AML • Ziftomenib combination studies in GIST and other cancers • KO-2806 and tipifarnib oncology product candidates • Kyowa Kirin collaboration and clinical supply services - **Commercial oncology product** (3%) — Approved and marketed cancer therapy sold in the United States under the KOMZIFTI brand. - **Clinical-stage oncology pipeline** (72%) — Investigational small-molecule programs targeting AML, GIST and other solid tumors. - **Collaboration and license revenue** (25%) — Upfront, milestone and service revenue from the Kyowa Kirin partnership. - KOMZIFTI (ziftomenib), an oral menin inhibitor for NPM1-mutated AML - Ziftomenib combination regimens in newly diagnosed and relapsed AML - Ziftomenib studies in gastrointestinal stromal tumors (GIST) - KO-2806, a next-generation oncology candidate in development - Tipifarnib and other small-molecule cancer pathway programs - Kyowa Kirin collaboration, licensing and clinical supply arrangements ## Customers Kura sells KOMZIFTI through specialty distributors and specialty pharmacies in the United States, which then supply pharmacies, health care providers and patients. Its broader economic customers are oncology clinicians, academic and community cancer centers, and payors that determine access and reimbursement for the drug. Collaboration revenue is driven by Kyowa Kirin under the license and clinical supply agreements. - **Specialty distributors and specialty pharmacies** (primary) — They purchase KOMZIFTI in the U.S. and resell it to providers and patients, making them the direct commercial channel. - **Oncology physicians and treatment centers** (primary) — Hematologists and oncologists choose whether to use KOMZIFTI or trial combinations in AML and other cancers. - **Third-party payors** (primary) — Commercial and government payors determine coverage, prior authorization and patient access, which directly affects adoption. - **Kyowa Kirin** (secondary) — The collaboration partner provides funding, services and commercial support under the license agreement. - **Clinical trial investigators and research sites** (secondary) — Academic and community sites enroll patients in ziftomenib and other pipeline studies to advance approvals. - Specialty distributors and specialty pharmacies buy KOMZIFTI for U.S. resale - Oncologists and hematology centers prescribe ziftomenib-based therapy - Payors influence uptake through coverage and reimbursement decisions - Academic and community cancer accounts are targeted for launch adoption - Kyowa Kirin funds part of development through collaboration agreements ## Geography Kura is headquartered in the United States and generates product revenue from U.S. sales of KOMZIFTI. Its development footprint is broader, with patent filings and clinical or regulatory activity across the U.S., Europe, China, Japan and other foreign jurisdictions. Geography matters mainly through U.S. commercialization, global intellectual property protection and the location of clinical development and partnering activity. - **United States** (100%) — KOMZIFTI product revenue was recognized in the United States. - United States is the only disclosed product revenue market for KOMZIFTI - U.S. commercialization depends on specialty pharmacy and distributor access - Europe, China and Japan are relevant for patent protection and future expansion - Clinical development is global in scope through trials and IP filings - Kyowa Kirin partnership adds cross-border collaboration exposure ## Strategy Kura’s strategy is to build KOMZIFTI into the anchor commercial product while expanding ziftomenib across the AML treatment continuum through combination trials and registrational studies. At the same time, it is using the Kyowa Kirin partnership to support development funding and commercialization execution, while advancing next-generation menin inhibitors and other pipeline assets to broaden the long-term franchise. - **Commercialize KOMZIFTI in U.S. AML** (short-term) — The approved product is the first source of product revenue and the base for future oncology franchise growth. - **Expand ziftomenib into frontline AML** (medium-term) — Frontline AML is a larger market than relapsed/refractory disease and could materially expand the addressable patient pool. - **Broaden the pipeline beyond AML** (medium-term) — Additional indications reduce dependence on a single asset and create optionality if AML competition intensifies. - **Maintain financing flexibility** (short-term) — The company remains cash-consuming and needs capital to fund trials, launch activities and manufacturing scale-up. - Drive adoption of KOMZIFTI in relapsed/refractory NPM1-mutated AML - Expand ziftomenib into frontline AML with Phase 3 registrational trials - Use combination studies to widen addressable AML patient populations - Leverage Kyowa Kirin for funding, access and commercial execution - Advance KO-7246 and other next-generation menin inhibitor programs ## Risks Kura remains highly dependent on ziftomenib, so clinical, regulatory or commercial setbacks could materially impair the business. The company also faces intense competition in oncology, reimbursement pressure, launch execution risk and ongoing financing needs because it is still funding a large development pipeline and a new commercial product. - **Dependence on ziftomenib success** [high] — The company’s value creation is concentrated in one lead asset across multiple indications. - **Clinical and regulatory failure** [high] — Product candidates must succeed in registrational trials and obtain FDA approval before commercialization. - **Competitive pressure in oncology** [high] — Large pharma and biotech competitors may launch faster, be safer or more effective, reducing market share. - **Reimbursement and access risk** [medium] — Coverage decisions and prior authorization can slow adoption of a newly launched specialty drug. - **Financing risk** [high] — The company has a history of operating losses and needs substantial funding for trials and commercialization. - Heavy dependence on ziftomenib creates single-asset concentration risk - Clinical trials may fail or miss endpoints, delaying approvals - AML competition may reach market sooner or with better profiles - Payor coverage and reimbursement can limit KOMZIFTI uptake - Commercial launch execution depends on distributors and specialty pharmacies - Additional capital may be needed if operating losses continue ## Accounting The most important accounting judgments are revenue recognition for KOMZIFTI sales and collaboration revenue from the Kyowa Kirin agreements. Clinical trial accruals, variable consideration such as rebates and co-pay assistance, and estimates around milestone or service obligations can materially affect reported revenue and expenses, especially as the company transitions from development-stage to commercial-stage operations. - **Net product revenue estimation** — Affects reported product revenue and gross-to-net deductions - **Collaboration and license revenue recognition** — Can create uneven quarterly revenue recognition - **Clinical trial accruals** — Can shift expense recognition between periods - **Commercial launch reserves** — May affect margins and near-term earnings volatility - KOMZIFTI net product revenue depends on rebates, discounts and co-pay estimates - Collaboration revenue requires judgment on license and service performance obligations - Clinical trial accruals affect R&D expense timing and comparability - Commercial launch creates new estimates for returns, allowances and inventory - Potential milestone payments and royalties may create lumpy revenue recognition --- *Last updated: 2026-04-28T20:20:44.722702+00:00*